SCHEMBL3568692

SCHEMBL3568692

Cc1cnc(C)c(Cn2c(C(=O)Nc3ccc4c(c3)nc(C)n4C)cc3cc(F)ccc32)n1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.49
NPC1 O15118 7/20 0.49
MAPT P10636 5/20 0.49
ATM Q13315 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.46
GLA P06280 1/20 0.46
PTGDR2 Q9Y5Y4 4/20 0.45
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
RECQL P46063 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
ECE1 P42892 1/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3573887 0.93 RAB9A (0.49) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL3577108 0.87 RAB9A (0.50) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL3574726 0.85 RAB9A (0.50) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL3570067 0.83 RAB9A (0.49) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL3570499 0.83 RAB9A (0.51) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL3153127 0.82 RAB9A (0.60) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL15361982 0.82 RAB9A (0.52) RAB9ANPC1MAPTATMSMN1; SMN2
Hydrochloric Acid SCHEMBL3573666 0.82 RAB9A (0.52) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL2815836 0.78 RAB9A (0.54) RAB9ANPC1MAPTATMSMN1; SMN2
SCHEMBL2813387 0.77 RAB9A (0.55) RAB9ANPC1MAPTATMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735432-B2 N-(Heteroaryl)-1-heteroarylalky1-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2014-05-27 US disclosed
EP-1910335-B1 N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2013-11-06 EP disclosed
US-20130046095-A1 N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof DUBOIS LAURENT (FR) 2013-02-21 US disclosed
US-8318775-B2 N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI (FR) 2012-11-27 US disclosed
US-20100222368-A1 N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-09-02 US disclosed
US-7745467-B2 N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-06-29 US disclosed
US-20080146646-A1 N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222368-A1 N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof IDO1, IDO2, CNR2 RAB9A 2329/4885NPC1 230/4885MAPT 3396/4885
US-20130046095-A1 N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof IDO1, IDO2, CNR2 RAB9A 2329/4885NPC1 230/4885MAPT 3396/4885
US-20080146646-A1 N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof IDO1, IDO2, CNR2 RAB9A 2329/4885NPC1 230/4885MAPT 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.